Lead Identification and Optimization
Global BDI can provide our clients a network whose members perform all elements of the early drug discovery process: screening of chemical libraries that provide a broad range of diversity across several target families; optimization of hits via medicinal chemistry and expertise in identifying suitable IP space; ADMET and cellular assays to provide biological data to become part of the iterative process of identifying suitable lead compounds. Targets include kinases, proteases, phosphatases, GPCRs and epigenetic elements such as HDACs and SIRTs. Global BDI is available to co-ordinate these various functions and to oversee the whole process for the client, if needed.
- Screen Diverse Library for Hits
- Medicinal Chemistry